FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012161432> ?p ?o ?g. }

• W2012161432 endingPage "e46511" @default.
• W2012161432 startingPage "e46511" @default.
• W2012161432 abstract "Background New vessel formation plays a pivotal role in the pathogenesis of neovascular-related diseases. Endothelial progenitor cells (EPCs) were found to contribute to neovascular-related diseases and interference with EPC neovascularization may be a novel target for these diseases. Zoledronate (Zol) was reported to exhibit anti-angiogenic effect. Basing on these evidences, we proposed that Zol may affect EPC function to exert novel anti-angiogenic effect. In this study, we therefore investigated the effects of Zol on multiple aspects of EPC function and explored the underlying mechanisms involved. Methodology/Principal Findings EPCs were cultured from bone marrow derived mononuclear cells. The potential effects of Zol on Angiotensin II (Ang II)-stimulated EPC proliferation, migration, adhesion, in vitro tube formation were investigated. The results showed that Ang II (1 µM) enhanced EPC migration, adhesion, in vitro tube formation but had no effect on cell proliferation. Zol (75 and 100 µM) inhibited proliferation of EPCs and 50 µM geranylgeranyol (GGOH) could reverse the decrease of EPC proliferation. We found for the first time that Zol (50–100 µM) dose dependently attenuated migration, adhesion, and in vitro tube formation of EPCs stimulated by Ang II. GGOH could reverse the attenuation of EPC function induced by Zol. However, Zol did not induce EPC apoptosis. In addition, the underlying mechanisms were determined. The results revealed that Zol markedly down-regulated active RhoA stimulated by Ang II and inhibited the phosphorylation of Erk1/2 and JNK. Moreover, RhoA silencing resulted in a notable inhibition of EPC in vitro tube formation, suggesting that RhoA suppression played a pivotal role in Zol antiangiogenic effect. Conclusions/Significance These findings suggested that Zol attenuated the promotion of EPC function stimulated by Ang II and exhibited novel antiangiogenic effect via RhoA and MAPK signaling. Thus, Zol may be served as a novel therapeutic agent for neovascular-related diseases treatment." @default.
• W2012161432 created "2016-06-24" @default.
• W2012161432 creator A5011723398 @default.
• W2012161432 creator A5021771824 @default.
• W2012161432 creator A5047470425 @default.
• W2012161432 creator A5054709496 @default.
• W2012161432 creator A5067483347 @default.
• W2012161432 creator A5074112736 @default.
• W2012161432 date "2012-10-11" @default.
• W2012161432 modified "2023-10-16" @default.
• W2012161432 title "Zoledronate Attenuates Angiogenic Effects of Angiotensin II-Stimulated Endothelial Progenitor Cells via RhoA and MAPK Signaling" @default.
• W2012161432 cites W169014411 @default.
• W2012161432 cites W1947874101 @default.
• W2012161432 cites W1973023022 @default.
• W2012161432 cites W1981192304 @default.
• W2012161432 cites W1981980281 @default.
• W2012161432 cites W199468027 @default.
• W2012161432 cites W2001216358 @default.
• W2012161432 cites W2003842905 @default.
• W2012161432 cites W2006473647 @default.
• W2012161432 cites W2017763556 @default.
• W2012161432 cites W2018037431 @default.
• W2012161432 cites W2019731805 @default.
• W2012161432 cites W2027359061 @default.
• W2012161432 cites W2039175323 @default.
• W2012161432 cites W2039656447 @default.
• W2012161432 cites W2047102045 @default.
• W2012161432 cites W2053704719 @default.
• W2012161432 cites W2054028666 @default.
• W2012161432 cites W2054190158 @default.
• W2012161432 cites W2059481840 @default.
• W2012161432 cites W2062743508 @default.
• W2012161432 cites W2063992586 @default.
• W2012161432 cites W2066407369 @default.
• W2012161432 cites W2067415148 @default.
• W2012161432 cites W2067921316 @default.
• W2012161432 cites W2079740791 @default.
• W2012161432 cites W2080373577 @default.
• W2012161432 cites W2097907656 @default.
• W2012161432 cites W2103011422 @default.
• W2012161432 cites W2106530343 @default.
• W2012161432 cites W2116877228 @default.
• W2012161432 cites W2121193141 @default.
• W2012161432 cites W2124763090 @default.
• W2012161432 cites W2127872440 @default.
• W2012161432 cites W2129988610 @default.
• W2012161432 cites W2132729704 @default.
• W2012161432 cites W2134795480 @default.
• W2012161432 cites W2136492061 @default.
• W2012161432 cites W2138240434 @default.
• W2012161432 cites W2139641836 @default.
• W2012161432 cites W2144860907 @default.
• W2012161432 cites W2145639716 @default.
• W2012161432 cites W2146672236 @default.
• W2012161432 cites W2157120864 @default.
• W2012161432 cites W2165929279 @default.
• W2012161432 cites W2314248511 @default.
• W2012161432 cites W2324677651 @default.
• W2012161432 cites W2333866106 @default.
• W2012161432 doi "https://doi.org/10.1371/journal.pone.0046511" @default.
• W2012161432 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3469623" @default.
• W2012161432 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23071580" @default.
• W2012161432 hasPublicationYear "2012" @default.
• W2012161432 type Work @default.
• W2012161432 sameAs 2012161432 @default.
• W2012161432 citedByCount "14" @default.
• W2012161432 countsByYear W20121614322014 @default.
• W2012161432 countsByYear W20121614322015 @default.
• W2012161432 countsByYear W20121614322016 @default.
• W2012161432 countsByYear W20121614322017 @default.
• W2012161432 countsByYear W20121614322018 @default.
• W2012161432 countsByYear W20121614322019 @default.
• W2012161432 countsByYear W20121614322020 @default.
• W2012161432 countsByYear W20121614322021 @default.
• W2012161432 crossrefType "journal-article" @default.
• W2012161432 hasAuthorship W2012161432A5011723398 @default.
• W2012161432 hasAuthorship W2012161432A5021771824 @default.
• W2012161432 hasAuthorship W2012161432A5047470425 @default.
• W2012161432 hasAuthorship W2012161432A5054709496 @default.
• W2012161432 hasAuthorship W2012161432A5067483347 @default.
• W2012161432 hasAuthorship W2012161432A5074112736 @default.
• W2012161432 hasBestOaLocation W20121614321 @default.
• W2012161432 hasConcept C137738243 @default.
• W2012161432 hasConcept C170493617 @default.
• W2012161432 hasConcept C185592680 @default.
• W2012161432 hasConcept C201750760 @default.
• W2012161432 hasConcept C202751555 @default.
• W2012161432 hasConcept C2777093181 @default.
• W2012161432 hasConcept C2778271429 @default.
• W2012161432 hasConcept C2780152582 @default.
• W2012161432 hasConcept C2780394083 @default.
• W2012161432 hasConcept C28328180 @default.
• W2012161432 hasConcept C2908929049 @default.
• W2012161432 hasConcept C502942594 @default.
• W2012161432 hasConcept C55493867 @default.
• W2012161432 hasConcept C62112901 @default.
• W2012161432 hasConcept C62478195 @default.
• W2012161432 hasConcept C71924100 @default.

• next